First-line management of metastatic non-small cell lung cancer: An Indian perspective

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
Umfang
Online-Ressource
Sprache
Englisch

Erschienen in
First-line management of metastatic non-small cell lung cancer: An Indian perspective ; volume:08 ; number:02 ; year:2019 ; pages:073-079
South Asian journal of cancer ; 08, Heft 02 (2019), 073-079

Beteiligte Personen und Organisationen
Ghadyalpatil, Nikhil Suresh
Pandey, Avinash
Krishnamani, Iyer
Srinivas, Chilukuri
Rafiq, Shabnam J.
Hingmire, Sachin S.
Maturu, Nagarjuna
Reddy, Ragotham
Kumar, Kiran K.
Sreekanth, K.
Gurram, Bharath Chandra
Parikh, P. M.

DOI
10.4103/sajc.sajc_294_18
URN
urn:nbn:de:101:1-2021021720135718224838
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
15.08.2025, 07:24 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Ghadyalpatil, Nikhil Suresh
  • Pandey, Avinash
  • Krishnamani, Iyer
  • Srinivas, Chilukuri
  • Rafiq, Shabnam J.
  • Hingmire, Sachin S.
  • Maturu, Nagarjuna
  • Reddy, Ragotham
  • Kumar, Kiran K.
  • Sreekanth, K.
  • Gurram, Bharath Chandra
  • Parikh, P. M.

Ähnliche Objekte (12)

Pembrolizumab as first-line treatment for metastatic uveal melanoma

Pembrolizumab as first-line treatment for metastatic uveal melanoma

Immunotherapy for metastatic melanoma—from little benefit to first-line treatment

Immunotherapy for metastatic melanoma—from little benefit to first-line treatment

Recent Advances in First-Line Management of Metastatic Renal Cell Carcinoma

Recent Advances in First-Line Management of Metastatic Renal Cell Carcinoma

Randomized phase II study with two gemcitabine- and docetaxel-based combinations as first-line chemotherapy for metastatic non-small cell lung cancer

Randomized phase II study with two gemcitabine- and docetaxel-based combinations as first-line chemotherapy for metastatic non-small cell lung cancer

Identifying key circulating tumor DNA parameters for predicting clinical outcomes in metastatic non-squamous non-small cell lung cancer after first-line chemoimmunotherapy

Identifying key circulating tumor DNA parameters for predicting clinical outcomes in metastatic non-squamous non-small cell lung cancer after first-line chemoimmunotherapy

NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy

NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy

AIH Therapy: Beyond First-Line

AIH Therapy: Beyond First-Line

Time-dependent efficacy analysis of first-line immunotherapies for advanced non–small cell lung cancer

Time-dependent efficacy analysis of first-line immunotherapies for advanced non–small cell lung cancer

First-line treatment of EGFR-mutated nonsmall cell lung cancer : critical review on study methodology

First-line treatment of EGFR-mutated nonsmall cell lung cancer : critical review on study methodology

Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?

Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?

First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1

First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1

Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer

Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer

Verbundene Objekte